Monocyte to HDL Cholesterol Ratio Predicts Coronary Artery Disease Severity and Future Major Cardiovascular Adverse Events in Acute Coronary Syndrome

Heart Lung and Circulation

Volumn 25, Issue 11, 2016, Pages 1077-1086

  Cetin, Mehmet Serkan ^a   Ozcan Cetin, Elif Hande ^a   Kalender, Erol ^a   Aydin, Selahattin ^a   Topaloglu, Serkan ^a   Kisacik, Halil Lutfi ^a   Temizhan, Ahmet ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

Acute coronary syndrome; Gensini score; Inflammation; Monocyte to HDL ratio; SYNTAX score

Indexed keywords

C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; ADULT; ANALYTICAL PARAMETERS; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GENSINI SCORE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCYTE; MONOCYTE TO HIGH DENSITY LIPOPROTEIN CHOLESTEROL RATIO; NEUTROPHIL LYMPHOCYTE RATIO; PERSONALIZED MEDICINE; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; STENT THROMBOSIS; SYNTAX SCORE; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; LEUKOCYTE COUNT; SEVERITY OF ILLNESS INDEX;

ACUTE CORONARY SYNDROME; ADULT; AGED; BIOMARKERS; CHOLESTEROL, HDL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTES; SEVERITY OF ILLNESS INDEX;

EID: 84963934395     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2016.02.023     Document Type: Article

References (25)

1. [1] Ancuta, P., Wang, J., Gabuzda, D., CD16+ monocytes produce IL-6, CCL2, and matrix metalloproteinase-9 upon interaction with CX3CL1-expressing endothelial cells. J. Leukoc. Biol. 80 (2006), 1156–1164.
2. [2] Parthasarathy, S., Barnett, J., Fong, L.G., High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim. Biophys. Acta. 1044 (1990), 275–283.
3. [3] Westerterp, M., Gourion-Arsiquaud, S., Murphy, A.J., Shih, A., Cremers, S., Levine, R.L., et al. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. Cell Stem Cell. 11 (2012), 195–206.
4. [4] Wang, N., Lan, D., Chen, W., Matsuura, F., Tall, A.R., ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 9774–9779.
5. [5] Kanbay, M., Solak, Y., Unal, H.U., Kurt, Y.G., Gok, M., Cetinkaya, H., et al. Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int. Urol. Nephrol. 46 (2014), 1619–1625.
6. [6] Canpolat, U., Aytemir, K., Yorgun, H., Şahiner, L., Kaya, E.B., Çay, S., et al. The role of preprocedural monocyte-to-high-density lipoprotein ratio in prediction of atrial fibrillation recurrence after cryoballoon-based catheter ablation. Europace. 17:12 (2015), 1807–1815.
7. [7] Canpolat, U., Çetin, E.H., Cetin, S., Aydin, S., Akboga, M.K., Yayla, C., et al. Association of Monocyte-to-HDL Cholesterol Ratio with Slow Coronary Flow is Linked to Systemic Inflammation. Clin. Appl. Thromb. Hemost., 2015.
8. [8] Cetin, E.H.O., Cetin, M.S., Canpolat, U., Aydin, S., Topaloglu, S., Aras, D., et al. Monocyte/HDL-cholesterol ratio predicts the definite stent thrombosis after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. Biomark. Med. 9 (2015), 967–977.
9. [9] Karataş, M.B., Çanga, Y., Özcan, K.S., İpek, G., Güngör, B., Onuk, T., et al. Monocyte to high-density lipoprotein ratio as a new prognostic marker in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am. J. Emerg. Med., 2015.
10. [10] Thygesen, K., Alpert, J.S., Jaffe, A.S., Simoons, M.L., Chaitman, B.R., White, H.D., et al. Third universal definition of myocardial infarction. J. Am. Coll. Cardiol. 60 (2012), 1581–1598.
11. [11] Thygesen, K., Alpert, J.S., White, H.D., Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J. Am. Coll. Cardiol. 50 (2007), 2173–2195.
12. [12] Hamm, C.W., Bassand, J.-P., Agewall, S., Bax, J., Boersma, E., Bueno, H., et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevatio. Eur. Heart J. 32 (2011), 2999–3054.
13. [13] Bassand, J.-P., Hamm, C.W., Ardissino, D., Boersma, E., Budaj, A., Fernández-Avilés, F., et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur. Heart J. 28 (2007), 1598–1660.
14. [14] Cutlip, D.E., Windecker, S., Mehran, R., Boam, A., Cohen, D.J., van Es, G.-A., et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 115 (2007), 2344–2351.
15. [15] Ghattas, A., Griffiths, H.R., Devitt, A., Lip, G.Y.H., Shantsila, E., Monocytes in coronary artery disease and atherosclerosis: where are we now?. J. Am. Coll. Cardiol. 62 (2013), 1541–1551.
16. [16] Mestas, J., Ley, K., Monocyte-endothelial cell interactions in the development of atherosclerosis. Trends Cardiovasc. Med. 18 (2008), 228–232.
17. [17] Woollard, K.J., Geissmann, F., Monocytes in atherosclerosis: subsets and functions. Nat. Rev. Cardiol. 7 (2010), 77–86.
18. [18] Qiao, J.H., Tripathi, J., Mishra, N.K., Cai, Y., Tripathi, S., Wang, X.P., et al. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Am. J. Pathol. 150 (1997), 1687–1699.
19. [19] Palmerini, T., Coller, B.S., Cervi, V., Tomasi, L., Marzocchi, A., Marrozzini, C., et al. Monocyte-derived tissue factor contributes to stent thrombosis in an in vitro system. J. Am. Coll. Cardiol. 44 (2004), 1570–1577.
20. [20] Murphy, A.J., Woollard, K.J., High-density lipoprotein: a potent inhibitor of inflammation. Clin. Exp. Pharmacol. Physiol. 37 (2010), 710–718.
21. [21] Murphy, A.J., Woollard, K.J., Hoang, A., Mukhamedova, N., Stirzaker, R.A., McCormick, S.P.A., et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler. Thromb. Vasc. Biol. 28 (2008), 2071–2077.
22. [22] Cutlip, D.E., Baim, D.S., Ho, K.K., Popma, J.J., Lansky, A.J., Cohen, D.J., et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation. 103 (2001), 1967–1971.
23. [23] van der Laan, A.M., Hirsch, A., Robbers, L.F.H.J., Nijveldt, R., Lommerse, I., Delewi, R., et al. A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: monocytes and myocardial infarction. Am. Heart J., 163, 2012 57–65.e2.
24. [24] Kontush, A., Chapman, M.J., Antiatherogenic small, dense HDL–guardian angel of the arterial wall?. Nat. Clin. Pract. Cardiovasc. Med. 3 (2006), 144–153.
25. [25] Boisvert, W.A., Black, A.S., Curtiss, L.K., ApoA1 reduces free cholesterol accumulation in atherosclerotic lesions of ApoE-deficient mice transplanted with ApoE-expressing macrophages. Arterioscler. Thromb. Vasc. Biol. 19 (1999), 525–530.